ArticleHuman genetics2025
Expanding the phenotypic spectrum of PROK2/PROKR2: a recall-by-genotype study.
Article in Human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetics of Idiopathic Hypogonadotropic HypogonadismJournal of clinical research in pediatric endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Rare variants in prokineticin 2 pathway genes (PROK2; PROKR2), cause isolated hypogonadotropic hypogonadism (IHH) in humans, leading to pubertal failure and infertility. In addition to reproduction, this pathway is also implicated in cardiovascular, metabolic, and inflammatory regulation. The role of naturally occurring PROK2/R2 variants in the general population remains unknown. Thus, we aimed to investigate the role of PROK2/R2 variants in the overall human health. We performed a recall-by-genotype study in rare PROK2/R2 variant carriers and non-carrier controls from a large hospital dataset [Massachusetts General Brigham Biobank (MGBB)]. All recalled participants underwent medical history, physical exam, completed detailed questionnaires and laboratory evaluation including a frequently sampled intravenous glucose tolerance test. Continuous and categorical variables were analyzed with a t-test/non-parametric Wilcoxon rank sum test and a Fisher's exact test, respectively. Twenty-five rare PROKR2 variant carriers (11 males and 14 females, mean age 45.6 years ± SD 11.7) and 24 non-carrier controls (16 males and 8 females, mean age 44.8 years ± SD 10) were recruited. Male variant carriers were more likely to seek fertility evaluation compared to non-carrier controls (p = 0.03) and carriers of the founder PROKR2 (p.L173R) variant (44% of the cohort) in both sexes were more likely to be diagnosed with lower gastrointestinal phenotypes compared to controls (p = 0.02). This novel clinical association is in line with the reported role of prokineticin 2 in intestinal smooth muscle function in preclinical models. Rare heterozygous PROK2/R2 variants contribute to known reproductive and novel gastrointestinal phenotypes within a hospital-based population cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.